Intertrade Dental to distribute Zila’s cancer screening products

Intertrade has placed orders for ViziLite Plus and plans to immediately begin training its sales representatives and preparing the market for the product launch.

Zila’s ViziLite Plus with TBlue is said to be the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer.

David Bethune chairman and CEO of Zila, said: “ViziLite Plus will provide dental professionals in Greece and Cyprus with an effective screening tool in the fight against oral cancer. Greece and Cyprus represent good markets in our continuing efforts to expand our geographical footprint for ViziLite Plus.”